Lymphoma: all 5,624 studies
Page 35 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.
- Cell-free Circulating DNA in Primary Cutaneous LymphomasCompletedNCT02883517
- Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell LymphomaStatus unknownNCT02879526Phase 2
- Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma PatientsCompletedNCT02877550Phase 1
- Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell LymphomasWithdrawnNCT02875002Phase 1
- Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell LymphomaStatus unknownNCT02871869Phase 2/3
- A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma PatientsCompletedNCT02867566Phase 3
- Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent LesionsStatus unknownNCT02867553Phase 3
- Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell LymphomaStatus unknownNCT02856997Phase 2
- A Study of Mitoxantrone Hydrochloride Liposome InfusionStatus unknownNCT02856685Phase 1/2
- Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and LymphomaStatus unknownNCT02851589Phase 1/2
- Signal Detection in Monoclonal and New Agents in LymphomaCompletedNCT02849912
- Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric OncologyCompletedNCT02847130
- p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid MalignanciesCompletedNCT02846935Early Phase 1
- a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell MalignanciesStatus unknownNCT02846584Phase 2
- Combination of Rituximab and NK Immunotherapy for B LymphomaCompletedNCT02843061Phase 1/2
- R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor PrognosisStatus unknownNCT02842931Phase 3
- Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell LymphomaStatus unknownNCT02842138Phase 1
- Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell LymphomaCompletedNCT02840539Phase 2
- Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV InfectionCompletedNCT02836925Phase 2
- Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid TumorsStatus unknownNCT02836834Phase 1
- BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's LymphomaStatus unknownNCT02836639Phase 2
- Clinical Cohort of Lymphoma Patients in MalawiActive, not recruitingNCT02835911
- Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL SubjectsActive, not recruitingNCT02825836Phase 1/2
- Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell LymphomaCompletedNCT02825147Phase 2
- Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or MalignanciesNo longer availableNCT02822495
- CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and LymphomaStatus unknownNCT02819583Phase 1/2
- A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and LymphomasCompletedNCT02812875Phase 1
- Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCLTerminatedNCT02811783Phase 3
- Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma PatientsCompletedNCT02809573Phase 1
- An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative ColitisActive, not recruitingNCT02808780
- Social Inequalities in the Participation and Activity in Children and Adolescents With Hodgkin-lymphomaStatus unknownNCT02808520
- Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell LymphomaTerminatedNCT02808091Phase 2
- PEG-rhG-CSF in Patients With Lymphoma Receiving ChemotherapyCompletedNCT02805218Phase 4
- Low-dose Radiotherapy for Diffuse Large B-cell LymphomaStatus unknownNCT02803840Phase 2
- Genetic Study of Families With High Frequency of Hodgkin LymphomaCompletedNCT02795013
- Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins LymphomaTerminatedNCT02793583Phase 2/3
- Durvalumab in Pediatric and Adolescent PatientsCompletedNCT02793466Phase 1
- Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic ToolStatus unknownNCT02791217
- A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell LymphomasCompletedNCT02788916
- Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell LymphomasCompletedNCT02783625Phase 1
- An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)CompletedNCT02782845Phase 4
- AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT02780830Phase 1
- Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid MalignanciesWithdrawnNCT02780011Phase 1
- Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)Status unknownNCT02779101Phase 2
- CNS Prophylaxis in Diffuse Large B-cell LymphomaStatus unknownNCT02777736Phase 3
- A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell LymphomaWithdrawnNCT02776891Phase 2
- Study of ACTR087 in Subjects With Relapsed or Refractory B-cell LymphomaCompletedNCT02776813Phase 1
- Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell LymphomaStatus unknownNCT02767674Phase 3
- MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell LymphomaCompletedNCT02764281Not applicable
- CyBeR Association in Relapsed/Refractory DLBCLStatus unknownNCT02758925Phase 2
- A Clinical Trial of Buparlisib and Ibrutinib in LymphomaCompletedNCT02756247Phase 1
- Chidamide Plus R-CHOP in Elderly DLBCLStatus unknownNCT02753647Phase 2
- Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell LymphomaStatus unknownNCT02753543Phase 2
- Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell LymphomaStatus unknownNCT02753062Phase 2
- Reduced Chemotherapy in Low Risk DLBCLStatus unknownNCT02752815Phase 4
- An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedNCT02752204Phase 2
- Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02750670Phase 2
- Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCLStatus unknownNCT02747732Phase 2
- Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in LymphomaWithdrawnNCT02743546Phase 1
- CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and LymphomaStatus unknownNCT02742727Phase 1/2
- A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDPCompletedNCT02741388Phase 1
- Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and LymphomasCompletedNCT02740270Phase 1
- the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)Status unknownNCT02737085Phase 1/2
- The Lymphoma Epidemiology of Outcomes (LEO) Cohort StudyWithdrawnNCT02736357
- A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaWithdrawnNCT02735876Phase 3
- MRI Compared to PET/CT for Staging and Treatment Response in LymphomaStatus unknownNCT02733887Not applicable
- GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell LymphomaCompletedNCT02733458Not applicable
- Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell LymphomaStatus unknownNCT02733380Phase 2
- DS-3201b in Participants With LymphomasActive, not recruitingNCT02732275Phase 1
- Marginal Zone Lymphoma Cohort in KoreaStatus unknownNCT02732236
- Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell LymphomaWithdrawnNCT02729961Phase 1/2
- Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell LymphomaStatus unknownNCT02728882Not applicable
- Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCTTerminatedNCT02728700Phase 1
- Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell LymphomaCompletedNCT02728531Phase 1
- Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For LymphomaWithdrawnNCT02724904Phase 1/2
- A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)CompletedNCT02723071Phase 1/2
- Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's LymphomaStatus unknownNCT02722733Phase 3
- Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma PatientsStatus unknownNCT02721407Phase 1
- Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell TransplantationCompletedNCT02719821Not applicable
- Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell LymphomaNo longer availableNCT02715843
- "MIRO" Molecularly Oriented Immuno-radio-therapyCompletedNCT02710643Phase 2
- Use of EBUS TBNA for Cell Culture as an Aid to Diagnose Lung Cancer and LymphomaCompletedNCT02710565Not applicable
- Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02708732
- Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)CompletedNCT02704832Not applicable
- A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin LymphomaTerminatedNCT02702141Phase 1
- Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed LymphomaWithdrawnNCT02701673Phase 1/2
- A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell LymphomasTerminatedNCT02700022Phase 1
- Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's LymphomaCompletedNCT02697552Phase 1
- Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry StudyCompletedNCT02691351
- Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHLActive, not recruitingNCT02690545Phase 1/2
- Combination of PCI-32765 With Obinutuzumab in Untreated Follicular LymphomaStatus unknownNCT02689869Phase 2
- Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/LymphomaStatus unknownNCT02685670Phase 1/2
- Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor MobilizersWithdrawnNCT02682953Phase 2
- The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell LymphomaCompletedNCT02679196Phase 1
- Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN StudyActive, not recruitingNCT02678299Phase 1/2
- Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)WithdrawnNCT02677948Phase 1/2
- Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular LymphomaCompletedNCT02677155Phase 2
- Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or LymphomasTerminatedNCT02675439Phase 1
- Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell LymphomaCompletedNCT02670616Phase 2
- Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.TerminatedNCT02670317Phase 2